belinostat
Sign in to saveAlso known as PXD-101, PXD101
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.
Key facts
- Drug.N
- 2
- Drug.H
- 14
- Drug.IUPAC_name
- (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
- Drug.image
- Belinostat.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Beleodaq
- Drug.pregnancy_US
- D
- Drug.legal_US
- Rx-only
- Drug.routes_of_administration
- Intravenous (IV)
- Drug.bioavailability
- 100% (IV)
- Drug.protein_bound
- 92.9–95.8%
- Drug.metabolism
- UGT1A1
- Drug.excretion
- Urine
- Drug.CAS_number
- 866323-14-0
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XH04
- Drug.PubChem
- 6918638
- Drug.DrugBank
- DB05015
via Wikipedia infobox
Research
396 papers- Belinostat.2012
- Belinostat.2006
- Belinostat Therapy and UGT1A1 Genotype.2012
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
- Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2017
via PubMed
Wikidata facts
- Has part
- carbon
- Mass
- 318.067428
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₅H₁₄N₂O₄S
- canonical SMILES
- C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
- NCI Thesaurus ID
- C48812
- isomeric SMILES
- O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
- subject has role
- antineoplastic
- Commons category
- Belinostat
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.
It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.
Excerpted from Wikipedia’s “belinostat” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0